Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

Publisher Website
Google Scholar
Abstract
To the editor: We read with interest the article by Metzelder et al showing sorafenib had antileukemic activity and could be given safely to patients with FLT-3 mutated AML relapsing after allogeneic stem cell transplantation (ASCT).[1][1] Because sorafenib delays progression of renal cell